- Patient data is underutilized
- Pre-clinical models lack translatability to human biology
- Disease heterogeneity is not captured
- Lack understanding of tumor microenvironment
- Lack understanding of drug mechanism of action
- Incomplete knowledge of clinical heterogeneity
How does Owkin’s AI-powered drug discovery work?
Global Head of Research and Chief Scientific Officer, Sanofi